LEARNING OBJECTIVES

• Understand the rationale for therapies targeting IDH1/2, FLT-3 and CD33
• Review clinical data, including the unique safety considerations, for these agents
• Highlight ongoing trials and future directions for research in this area

WEDNESDAY, JUNE 6, 2018

MUHC- GLEN
08:30 to 09:30
Block D, Room D.02.1312
Live on the Web! www.vpsolution.tv/vspo
Problems/Questions: 514 813-4510

HOPITAL MAISONNEUVE ROSEMONT
12:00-13:00
Room 0-80 (Pavillon Marcel Lamoureux)

THURSDAY, JUNE 7, 2018

JEJISH GENERAL HOSPITAL
12:30 to 13:30
Room E-711

SACRE COEUR HOSPITAL
15:00 to 16:00
Room G-4130

Refreshments will be served at each location.
To organize a videconference: vspo@mcgill.ca

This program has received an educational grant from:
AbbVie, Alexion, Amgen, Apobiotix, Astellas, AstaZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, Eli Lilly, Gilead, Janssen, Lundbeck, Merck, Novartis, Pfizer, Roche, Seattle Genetics, Shire